Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study

Table 2 Patients included in the study

	Study number	Study popul-ation	ARR	Serum aldosterone (nmol/L)	CT	¹³¹I-chol-scint	AVS	Diagnose	PAD
1	14	NSP	1.30	0.69	-	-	-	AH
2	1042	NSP	2.50	0.54	+ (L)	-	-	AH
3	1052	NSP	3.10	0.46	/	/	/	Normal
4	1065	NSP	4.30	0.64	+ (R)	-	Excluded
5	1092	NSP	1.50	0.75	/	/	/	Normal
6	1105	NSP	2.00	0.62	/	/	/	Normal
7	2002	SP	2.10	0.60	/	/	/	Normal
8	2006	SP	3.80	0.49	- (x2)	+ (B)	+ (L)	APA (L)	NAH
9	2007	SP	4.30	0.64	+ (R)	-	+ (R)	APA (R)	NAH
10	2010	SP	2.90	0.43	-(?L)	-	+ (L?)	APA/AH	Adenoma
11	2014	SP	4.50	0.68	-	- (?R)	+ (R)	APA (R)	NAH
12	2022	SP	6.80	1.29	-	-	-	AH
13	2036	SP	2.90	0.43	/	/	/	Normal
14	2037	SP	4.50	0.95	/	/	/	Normal
15	2042	SP	1.70	0.44	-	-	+ (L)	APA (L)	NAH
16	2049	SP	9.30	1.39	+	-	Excluded
17	2060	SP	3.30	0.89	+ (R)	-	+ (R)	APA (R)
18	2069	SP	1.64	0.56	/	/	/	Normal
19	2070	SP	2.40	0.88	+ (L)	-	-	AH
20	2074	SP	4.95	0.65	-	/	/	AH
21	2082	SP	3.80	0.50	-	/	/	AH
22	2083	SP	2.10	1.10	+ (R)	+ (R)	+ (R)	APA (R)	Adenoma
23	2084	SP	3.90	0.86	-	+ (L)	+ (L)	APA (L)	Adenoma
24	2086	SP	1.40	0.60	+ (L)	-	+ (L)	APA (L)	NAH
25	2099	SP	7.20	1.69	+ (L)	-	+ (L)	APA (L)	Adenoma
26	2100	SP	3.80	0.50	/	/	/	Normal
27	3005	SP	2.10	0.62	-		Excluded
28	3006	SP	3.50	0.94	-	-	failed

Population defines if the patient was screened in a non-selective (NSP) or a selective (SP) hypertensive population. Values for serum aldosterone and the ratio of s-aldosterone/plasma renin activity (ARR) at inclusion and results of the adrenal CT (CT), ¹³¹I-norcholesterol-scintigraphy (¹³¹I-chol-scint) and adrenal vein sampling (AVS) are given. For the CT, ¹³¹I-chol-scint and AVS the following symbols are used +, - , / and failed, for positive, bilateral overproduction of aldosterone, not executed and failed investigation respectively. The letters (L), (R) and (B) indicate left, right and bilateral respectively. In the diagnose column, Normal, AH and APA are used for normal ie no hyperaldosteronism, adrenal hyperplasia and aldosterone producing adenoma respectively. In the PAD column, NAH is used for cortical nodular hyperplasia and adenoma for cortical adenoma.

ISSN: 1472-6823